Competition record
Bausch Health
Deep profile · 1 linked library matter
Bausch Health sells branded drugs. Purchasers allege a deal delayed a generic of an IBS treatment. A 2023 case is still open, and Baltimore filed a follow-on in September 2026.
Overview
Bausch Health is a branded drug company. The product at issue in the purchaser cases is an IBS treatment. The allegation is a pay-for-delay style arrangement that kept a generic off the market.
A Rhode Island case dates to September 2023. Baltimore filed a follow-on on September 22, 2026. Neither filing is a finding that a payment was made or that it was illegal.
Patent settlements between brands and generics are common. They are unlawful only in specific circumstances, which the plaintiffs still have to prove.
Competition footprint
The theory is delayed generic entry, not a cartel among pharmacies.
Public payers and insurers are the purchasers bringing the cases.
No judgment is recorded here.
Consumer & business angle
Patients pay the copay on the brand while a generic is absent.
A generic manufacturer is the rival the settlement is alleged to have paid or constrained.
What to watch
- Whether the Baltimore follow-on survives dismissal.
- Any ruling on the 2023 purchaser case.
Markets
branded drugs · irritable bowel drugs · generic drugs
Also known as: bausch